SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-211584
Filing Date
2024-09-03
Accepted
2024-09-03 08:15:59
Documents
15
Period of Report
2024-09-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d873439d8k.htm   iXBRL 8-K 24142
2 EX-99.1 d873439dex991.htm EX-99.1 13281
6 GRAPHIC g873439g0902181422806.jpg GRAPHIC 2734
  Complete submission text file 0001193125-24-211584.txt   168020

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cogt-20240903.xsd EX-101.SCH 2513
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20240903_lab.xml EX-101.LAB 17955
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20240903_pre.xml EX-101.PRE 11239
17 EXTRACTED XBRL INSTANCE DOCUMENT d873439d8k_htm.xml XML 3710
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 241272088
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)